PMID- 28901323
OWN - NLM
STAT- MEDLINE
DCOM- 20180510
LR  - 20180510
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 13
IP  - 4
DP  - 2017
TI  - Human epidermal growth factor receptor 2 amplification detection by droplet 
      digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and 
      gastric cancer samples.
PG  - 730-734
LID - 10.4103/jcrt.JCRT_587_17 [doi]
AB  - OBJECTIVE: Human epidermal growth factor receptor 2 (HER2) is an important 
      biomarker for the precise individualized treatment including trastuzumab of 
      HER2-positive breast and gastric cancer. Immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) are the routine analyses for 
      formalin-fixed paraffin-embedded (FFPE) samples. However, IHC is variable and 
      depends on the evaluator, and FISH is a labor intensive and expensive method. We 
      evaluated the feasibility of droplet digital polymerase chain reaction (ddPCR) as 
      a precise and quantitative method for HER2 amplification test. MATERIALS AND 
      METHODS: We used ddPCR to confirm HER2 amplification status in 24 breast cancer 
      and 29 gastric cancer samples to validate the HER2 cutoff value in ddPCR. After 
      setting cutoff value, all the above-mentioned samples were tested by IHC. 
      Afterward, another 51 equivocal IHC 2+ gastric cancer samples were further 
      determined by FISH and ddPCR, respectively, and the concordance between ddPCR and 
      FISH was calculated. RESULTS: We set the HER2 cutoff value at 1.8. The 
      concordance rate of HER2 status between ddPCR and IHC was 94.4% (17 out of 18) in 
      24 breast cancer samples. In 29 gastric cancer specimens, the concordance rate of 
      HER2 amplification between ddPCR and IHC was 100% (22 out of 22). At last, 
      compared with FISH determined HER2 status, ddPCR HER2 scores correctly classified 
      44 of 51 cases with 86.3% concordance in 51 equivocal IHC 2+ gastric cancer 
      samples. CONCLUSIONS: ddPCR was able to identify HER2 amplification status in 
      breast and gastric cancers with precise correlation with IHC and FISH results. 
      This method might become a standard method for testing FFPE samples. However, the 
      technology requires further research.
FAU - Wang, Xingwen
AU  - Wang X
AD  - Cancer Center, Shandong Provincial Hospital Affiliated to Shandong University, 
      Shandong University, Jinan, Shandong, China.
FAU - Wu, Yunyan
AU  - Wu Y
AD  - Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Shandong University, Jinan, Shandong, China.
FAU - Song, Xueling
AU  - Song X
AD  - Clinical Skill Training Center, Shandong Provincial Hospital Affiliated to 
      Shandong University, Shandong University, Jinan, Shandong, China.
FAU - Sun, Chengtao
AU  - Sun C
AD  - Department of Otorhinolaryngology, Center for Radiation Oncology, Shandong 
      Provincial Hospital Affiliated to Shandong University, Shandong University, 
      Jinan, Shandong, China.
FAU - Wu, Changshun
AU  - Wu C
AD  - Department of Bone and Joint Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Shandong University, Jinan, Shandong, China.
FAU - Feng, Hong
AU  - Feng H
AD  - Cancer Center, Shandong Provincial Hospital Affiliated to Shandong University, 
      Shandong University, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Biomarkers, Tumor)
RN  - 1HG84L3525 (Formaldehyde)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Breast Neoplasms/*genetics/pathology
MH  - Female
MH  - Formaldehyde/chemistry
MH  - Gene Amplification/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Paraffin Embedding
MH  - Receptor, ErbB-2/*genetics/isolation & purification
MH  - Stomach Neoplasms/*genetics/pathology
EDAT- 2017/09/14 06:00
MHDA- 2018/05/11 06:00
CRDT- 2017/09/14 06:00
PHST- 2017/09/14 06:00 [entrez]
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2018/05/11 06:00 [medline]
AID - JCanResTher_2017_13_4_730_214480 [pii]
AID - 10.4103/jcrt.JCRT_587_17 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2017;13(4):730-734. doi: 10.4103/jcrt.JCRT_587_17.